Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
Breast Cancer Research and Treatment · 2025-02 · 209 (3) · 455-465
DOI: 10.1007/s10549-024-07595-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 08.01.2025. Verfasst von Roberta Scafetta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Selective Estrogen Receptor Modulators. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The management of hormone receptor-positive (HR +) breast cancer (BC) relies on endocrine therapy (ET), with a primary focus on disrupting estrogen receptor (ER) signaling due to its critical role in BC tumorigenesis and progression. While effective for both early-stage and advanced breast cancers, ET frequently encounters resistance mechanisms, including both ligand-dependent and ligand-independent trajectories, ultimately leading to disease progression. METHODS: We searched PubMed, EMBASE and Scopus databases to review the current evidence on the use of novel oral selective estrogen receptor degraders (SERDs) for the treatment of HR+ BC. CONCLUSIONS: Somatic activating mutations of the estrogen receptor 1 (ESR1) gene are known to sustain ER activity, boost ER-dependent gene transcription, and foster resistance to ET. The most significant gap remains after treatment failure with ET and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, where fulvestrant monotherapy typically results in a median progression-free survival of 2-3 months. Novel compounds, including oral SERDs, have been explored for their potential to overcome therapeutic resistance, both as monotherapy and in combination with other targeted therapies. Herein, we provide an overview on the latest findings on oral SERDs, examining their mechanism of action, safety data, and pharmacokinetics and pharmacodynamics profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
- Medical Oncology Department, Campus Bio-Medico University of Rome, Rome, Italy.
- Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy.
- Saint Camillus International, University of Health and Medical Sciences, Rome, Italy.
- Scientific Direction, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
- Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy. antonio.marra@ieo.it.
Zitieren
APA
Scafetta, R., Zagami, P., Del Re, M., Criscitiello, C., Marra, A., & Curigliano, G. (2025). Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences. Breast Cancer Research and Treatment, 209(3), 455-465. https://doi.org/10.1007/s10549-024-07595-1
Vancouver
Scafetta R, Zagami P, Del Re M, Criscitiello C, Marra A, Curigliano G. Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences. Breast Cancer Research and Treatment. 2025;209(3):455-465. doi:10.1007/s10549-024-07595-1
BibTeX
@article{Scafetta2025,
author = {Scafetta, Roberta and Zagami, Paola and Del Re, Marzia and Criscitiello, Carmen and Marra, Antonio and Curigliano, Giuseppe},
title = {Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences},
journal = {Breast Cancer Research and Treatment},
year = {2025},
volume = {209},
number = {3},
pages = {455--465},
doi = {10.1007/s10549-024-07595-1}
}
EUVIMED